138 related articles for article (PubMed ID: 23527672)
1. Samarium-153-lexidronam therapy for metastatic bone pain.
Ribera H
J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):80-1; discussion 81-2. PubMed ID: 23527672
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ
Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.
Menda Y; Bushnell DL; Williams RD; Miller S; Thomas MO
Clin Nucl Med; 2000 Sep; 25(9):698-700. PubMed ID: 10983757
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
5. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E
Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302
[TBL] [Abstract][Full Text] [Related]
6. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
Lam MG; de Klerk JM; Zonnenberg BA
J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
[TBL] [Abstract][Full Text] [Related]
7. Samarium-153 lexidronam for painful bone metastases.
Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
[No Abstract] [Full Text] [Related]
8. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
9. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I
Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329
[TBL] [Abstract][Full Text] [Related]
11. New use for radioisotope in prostate cancer.
Nelson R
Lancet Oncol; 2006 Jul; 7(7):539. PubMed ID: 16838440
[No Abstract] [Full Text] [Related]
12. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
Lin J; Sinibaldi VJ; Carducci MA; Denmeade S; Song D; Deweese T; Eisenberger MA
Urol Oncol; 2011; 29(6):670-5. PubMed ID: 19962920
[TBL] [Abstract][Full Text] [Related]
13. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
[TBL] [Abstract][Full Text] [Related]
14. Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005).
Barnard SM; Zuber RM; Moore AS
J Am Vet Med Assoc; 2007 Jun; 230(12):1877-81. PubMed ID: 17571994
[TBL] [Abstract][Full Text] [Related]
15. Samarium 153Sm lexidronam.
Lamb HM; Faulds D
Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
[TBL] [Abstract][Full Text] [Related]
16. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
Skalli S; Desruet MD; Bourre JC; Caravel JP; Vuillez JP
Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
Wang RF; Zhang CL; Zhu SL; Zhu M
Med Princ Pract; 2003; 12(2):97-101. PubMed ID: 12634464
[TBL] [Abstract][Full Text] [Related]
18. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases].
Velasco Latrás M; Carreras Coderch L; Antoñanzas Villar F; Coya Viña J; Martín Comín J; Martínez Carderón F; Nieto Martín-Bejarano J; Sáenz Cusí A; Serrano Bermúdez G; Echevarría Icaza A
Clin Transl Oncol; 2005 Jun; 7(5):198-204. PubMed ID: 15960931
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
